Sintx Technologies Stock Price, News & Analysis

SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company focused on silicon nitride–based technologies for medical and other high‑value applications. Headquartered in Salt Lake City, Utah, SINTX develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies that are used in surgical implants and infection‑prevention platforms. The company is active in the surgical and medical instrument manufacturing industry and the broader manufacturing sector.

Business focus and technology platform

According to its public disclosures, SINTX has built its business around a proprietary silicon nitride (Si₃N₄) materials platform. Its biomedical products are described as biocompatible, bioactive, antipathogenic, and having good bone affinity. Over thousands of medical devices manufactured with SINTX silicon nitride have been implanted in patients, and the company highlights nearly two decades of peer‑reviewed research supporting its technology. SINTX positions silicon nitride as a high‑performance biomaterial that can enhance clinical outcomes and patient safety.

The company’s activities span biomedical devices, polymer composites, and antipathogenic applications. It develops silicon nitride biomaterials and composites for implantable devices, and it has also advanced an antipathogenic platform for fabrics and fibrous materials. SINTX reports that its silicon nitride has been studied for antipathogenic behavior and osteogenic properties, and that PEEK‑based composites are valued for radiolucency and mechanical tunability when combined with silicon nitride.

Medical devices and reconstructive surgery

SINTX’s disclosures emphasize a focused commercialization plan centered on infection‑resistant silicon nitride devices and polymer composites. A key milestone for the company is U.S. Food and Drug Administration (FDA) 510(k) clearance for the SINAPTIC® Foot & Ankle Osteotomy Wedge System. This silicon nitride implant system is engineered for reconstructive foot and ankle surgery in the United States and combines the company’s proprietary biomaterial with surgeon‑informed implant designs and a planned sterile, single‑use instrument kit.

The SINAPTIC implant system is described as delivering stable correction in foot and ankle osteotomy procedures, with design elements that support precision fit, predictable technique, and compatibility with biologic augmentation. As cleared under the FDA submission, SINTX highlights several material‑level attributes of its silicon nitride relevant to the device, including:

• Pro‑osteogenic surface chemistry mechanisms associated with protein absorption and osteointegration compared to traditional biomaterials.
• Bacteriostatic surface properties that have been shown in laboratory and animal studies to repel and/or inhibit the growth of various types of bacteria.
• Hydrophilic behavior that attracts fluids, which the company associates with deterring bacterial colonization and supporting bone‑building mechanisms.
• Enhanced visibility on imaging, allowing clearer visualization of surrounding tissues on X‑ray and CT scans compared with metal implants.

SINTX has also announced a private label agreement to supply OsseoSculpt™, a biologic product designed to complement the SINAPTIC Foot & Ankle Osteotomy Wedge System. OsseoSculpt features a nanocrystalline HCA surface with a biomimetic pore architecture intended to provide an osteoconductive scaffold. The company markets this biologic alongside its SINAPTIC wedge system as a companion product to augment bone healing in indicated procedures.

Silicon nitride–PEEK composites and patient‑specific implants

SINTX has entered into a supply agreement with Evonik Corporation to manufacture the company’s proprietary silicon nitride–PEEK compound (SiN/PEEK), covered by U.S. Patent No. 10,806,831. Under this agreement, EVONIK produces the SiN/PEEK compound at commercial scale to SINTX specifications, enabling SINTX to manufacture AI‑assisted, 3D‑printed, patient‑specific implants using equipment at its U.S. production facility.

The SiN/PEEK combination is described by SINTX as aiming to deliver:

• Antipathogenic surface behavior intended to help reduce microbial adherence on implant surfaces.
• Osteogenic support to promote bone on‑growth and integration.
• Improved visualization versus standard PEEK for intra‑operative and post‑operative imaging.
• Design freedom via AI‑assisted additive manufacturing for patient‑specific geometries.
• Scalable, consistent filament to support high‑mix, low‑volume production typical of patient‑specific workflows.

The company notes that it has received physician requests to provide humanitarian‑use vertebral body replacement implants for orthopedic and neurosurgical oncology patients following tumor resections in the spine, and that it intends to use the SiN/PEEK compound to support regulatory clearances of patient‑matched and traditionally manufactured implantable devices.

Infection‑prevention and antipathogenic fabric technology

Beyond implants, SINTX has developed an antipathogenic fibrous materials platform based on silicon nitride. The United States Patent and Trademark Office has issued a Notice of Allowance for a patent application containing method claims covering the company’s antipathogenic fabric technology, complementing a previously allowed composition patent titled “Antipathogenic Fibrous Materials.” Together, these patent families provide coverage for both the composition of silicon nitride‑based antipathogenic fabrics and the methods used to produce and apply them.

SINTX states that these patents create an intellectual‑property barrier around surface‑level pathogen‑inactivation technology for use in:

• Wound dressings
• Surgical drapes and gowns
• Filtration media
• Personal protective equipment (PPE)
• High‑touch clinical surfaces

The company cites peer‑reviewed work showing rapid inactivation of coronaviruses and broad antimicrobial activity associated with silicon nitride, including data reporting high levels of viral reduction under laboratory conditions. SINTX notes that non‑woven fabrics containing optimized silicon nitride powder have demonstrated significant viral reduction, and it characterizes infection‑prevention as a large, multi‑segment opportunity across medical textiles, wound management, filtration/PPE, and healthcare infrastructure. The company has indicated plans to pursue licensing and co‑development partnerships with textile, wound care, and filtration/PPE partners, using its dual composition‑and‑method patent coverage to support various licensing structures.

Corporate and capital markets activity

SINTX’s shares trade on the Nasdaq Capital Market under the symbol SINT. The company uses a mix of equity financing tools, including at‑the‑market (ATM) offerings and warrant‑based financings, as described in its Form 8‑K filings. It has entered into an ATM Offering Agreement with H.C. Wainwright & Co., LLC to sell shares of common stock from time to time under an effective shelf registration statement, and it has also executed warrant inducement agreements that provide additional capital through the exercise of existing warrants and issuance of new warrants.

SINTX has also used asset acquisitions to expand its product portfolio. For example, it entered into an Asset Purchase Agreement to acquire substantially all assets of Sinaptic Surgical, LLC, related to foot and ankle implants. Consideration includes warrants that vest upon achieving specified regulatory and revenue milestones tied to foot and ankle implant products, as well as a royalty arrangement on certain net revenues. The company describes this transaction as aligned with its focus on foot and ankle reconstructive solutions.

Research, IP, and manufacturing base

SINTX emphasizes that its technology platform is supported by a strong patent portfolio, U.S.‑based manufacturing, and strategic industry partnerships. Its disclosures reference thousands of implanted devices since 2008 and a long history of peer‑reviewed research on silicon nitride’s biomaterial and antipathogenic properties. The company’s U.S. production facilities support manufacturing of silicon nitride ceramics, SiN/PEEK compounds, and related devices, and its partnerships with organizations such as EVONIK are intended to provide commercial‑scale polymer manufacturing capabilities.

Through these combined activities—medical device development, polymer composites for patient‑specific implants, and antipathogenic fabrics—SINTX presents itself as a specialist in high‑performance silicon nitride biomaterials serving both implantable device markets and broader infection‑prevention applications.